SRX3207

CAS No. 2254693-15-5

SRX3207( —— )

Catalog No. M33816 CAS No. 2254693-15-5

SRX3207 is an inhibitor of Syk and PI3K and relieves tumor immunosuppression.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 129 Get Quote
5MG 206 Get Quote
10MG 309 Get Quote
25MG 484 Get Quote
50MG 638 Get Quote
100MG 875 Get Quote
500MG 1755 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    SRX3207
  • Note
    Research use only, not for human use.
  • Brief Description
    SRX3207 is an inhibitor of Syk and PI3K and relieves tumor immunosuppression.
  • Description
    SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression.
  • In Vitro
    SRX3207 (10 μmol/L) is able to block p-AKT at concentration.SRX3207 has sufficient solubility in water (43 μmol/L).
  • In Vivo
    SRX3207 (10 mg/kg, orally) increases antitumor immune response.Animal Model:LLC or B16 or B16-OVA or CT26 (1 × 105) cells were injected subcutaneously into syngeneic mice.Dosage:10 mg/kg.Administration:Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21.Result:Blocked phosphorylation of Syk at 348 site and Y525/526 site.Blocked immunosuppressive MΦ polarization.Blocked tumor growth and increased survival effectively.
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    PI3K | Syk
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2254693-15-5
  • Formula Weight
    555.65
  • Molecular Formula
    C29H29N7O3S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 5 mg/mL (9.00 mM; Ultrasonic )
  • SMILES
    Cc1nn(cc1CN1CCC1)-c1ccnc(Nc2ccc(cc2)-c2csc3c2oc(cc3=O)N2CCOCC2)n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Shweta Joshi, et al. Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020.
molnova catalog
related products
  • PI3K/mTOR Inhibitor-...

    PI3K/mTOR Inhibitor-2 is a potent pan inhibitor of PI3K and mTOR with IC50s of 3.4, 34, 16,1 and 4.7 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR. PI3K/mTOR Inhibitor-2 has antitumor activity.

  • PI3K-IN-1

    PI3K-IN-1 is a potent inhibitor of PI3K.

  • GDC-0032

    GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with IC50 of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.